WO2003006007A1 - Use of compounds as functional antagonists to the central cannabinoid receptors - Google Patents
Use of compounds as functional antagonists to the central cannabinoid receptors Download PDFInfo
- Publication number
- WO2003006007A1 WO2003006007A1 PCT/EP2002/007722 EP0207722W WO03006007A1 WO 2003006007 A1 WO2003006007 A1 WO 2003006007A1 EP 0207722 W EP0207722 W EP 0207722W WO 03006007 A1 WO03006007 A1 WO 03006007A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fact
- use according
- chosen
- disorders
- residue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Definitions
- the present invention is related to the use of acylamides as functional antagonists to the central cannabinoid receptors. STATE OF THE ART
- Cannabis sativa in addition to being one of the most diffuse recreational drugs in the world, has been used for medical reasons for centuries for its multiple pharmacological effects, the use of which has, however, been limited in the last century mostly for its psychoactive effects on the CNS.
- the principal active component identified is ⁇ 9 -tetrahydrocannabinol ( ⁇ 9 -THC) which, in fact, in addition to possessing psychotropic activity, produces an innumerable series of pharmacological effects both in humans and in animals demonstrating therefore great therapeutic potential, however limited by the central effects mentioned.
- the so-called central receptor because it was initially identified in areas of the CNS and considered the molecular transducer of the central effects of cannabinoids and ii) the so-called peripheral receptor initially identified in peripheral tissues and in turn however considered the molecular transducer of the peripheral effects.
- the central receptors are present in fact in high concentrations in the CNS, and more precisely in the cerebral cortex, hippocampus, caudate-putamen nuclei, substantia nigra, pars reticulata, globus pallidus, endopeduncular nucleus, cerebellum and spinal medulla.
- central receptors are however also present at the peripheral level principally in correspondence with nerve endings as for example in the intestine, as well as on endothelium and on immunocompetent cells.
- peripheral receptors have been principally identified at the peripheral level and above all in immunocompetent cells as for example T- lymphocytes, mastocytes, macrophages, etc.
- the central receptors are considered to mediate not just the "undesired effects” of cannabinoids (such as the psychoactive effects, loss of memory and attention-span, loss of motor co-ordination etc.) but also some of their therapeutically “desired effects” (analgesic effect, anti-hyperalgic, appetite stimulation, ocular hypotension, etc.).
- the peripheral receptors like the central receptors present in the immunocompetent cells, have been associated with the more peripheral effects of cannabinoids as for example the anti-inflammatory effect (Amen A. 1999 ref. cit).
- cannabinomimetic molecules such as the classical cannabinoid agonists (e.g. ⁇ 8 -THC, ⁇ 6 -THC etc.) and non-classical cannabinoid and their derivatives (e.g. CP 55940, HU-210 etc.), derived from the endocannabinoids (e.g. metanandamide, etc.), aminoalkylindoles (e.g. Win 55-212) and molecules capable of interfering with the uptake and the inactivation of the endocannabinoids (e.g.
- AM 404 trifluoromethylketones, etc.
- synthetic derivatives have also been characterised, e.g. pyrrolic derivatives (e.g. SR141716, SR144528), with antagonistic activity towards cannabinoid receptors, believed to be useful in the control of eating disorders, in memory improvement and motor activity and for the weaning from dependency in tobacco as well as cannabis smokers (Ameri A. 1999 ref. cit).
- PEA N- acylethanolamides
- This family comprises derivatives of ethanolamine conjugated with acid radicals, both saturated (PEA) and unsaturated (ANA).
- ANA and PEA can be produced and released by neuronal cells following excitation suggesting that these molecules may act as neurotransmitter belonging to the endocannabinoids system.
- anandamide in vivo provokes cannabinoid-like effects, such as hypothermia, hypomotility, catalepsy, etc.
- these effects have never been reported after administration of PEA in vivo, a result compatible with the absence of affinity of this molecule for the central receptor.
- PEA and ANA are both able to exercise anti-inflammatory effects in vivo, there are disagreements regarding the capacity of PEA, in contrast to that of ANA, to interact with the peripheral cannabinoid receptors (Sugiura T. et al. 2000 J. Biol. Chem.
- PEA is capable of significantly reducing the release of pro- inflammatory mediators from stimulated mastocytes in vitro, through an action on the peripheral receptors expressed on these cells (Facci L et al. 1995 ref. cit), more recent experiments conducted on transfected cell lines overexpressing the peripheral receptor have demonstrated that PEA is not able to displace the binding of cannabinoidmimetic molecules to this receptor (Sugiura T. et al. 2000 ref. cit).
- PEA and analogues have been indicated as possessing neuroprotective activity in vitro and as such useful in pathological conditions associated with neuronal death (WO 9525509 and WO 9618600). This effect has been observed in vitro in newborn mouse cerebellum granule cells which express the peripheral receptor or a CB2-like receptor (Skaper S.D. et al. 1996 ref.cit). Furthermore, a patent application has recently been filed for the use of PEA as a cardio-protective (WO01/28588), an effect mediated also in this case likewise by peripheral receptors, because it is antagonised by SR 144528, antagonist of the peripheral receptor, and not by SR 141716, antagonist of the central receptor.
- Ri — CO — can be an acyl residue of a saturated organic acid, linear or branched comprising from 10 to 20 C atoms — N — R 2 can be:
- an aminohydroxyalkyl residue linear or branched comprising from 2 to 6 C atoms, optionally substituted with one or more aromatic groups on the alkyl chain
- - an aminoacid residue of the series ⁇ , ⁇ or ⁇ R 3 can be H or CH 3 or where -N — R 2 ,R 3 form with the N atom a cyclic aminoether comprising from 5 to 7 C atoms, optionally substituted with linear or branched alkyl groups, behave as functional antagonists of the central cannabinoid receptors. They can therefore be usefully employed as drugs in pathological states or disorders which can be controlled through a reduction of the functionality of these receptors or through a reduction of the effect of the same endocannabinoids caused by a reduced availability or affinity of the receptors.
- the subject of the present invention is the use of said saturated acylamides, or esters or salts of the same, for the preparation of pharmaceutical compositions for the treatment of pathological states or disorders connected with an altered functionality and/or "abusive" activation of the central cannabinoid receptors.
- the aims and advantages of the therapeutic use of the saturated acylamides as functional antagonists of central cannabinoid receptors in pathological states or disorders which can be controlled by reducing the functionality of these receptors or impeding the activity of endocannabinoids, subject of the present invention, will be better understood in the course of the following detailed description.
- the applicant has in fact found surprisingly that after repeated administration of saturated acid acylamides, a marked reduction in the receptor density of the central cannabinoid receptors at the level of the spinal medulla, and a reduction of the affinity constant (Kd), still for these receptors, in different cerebral areas (cerebellum, cortex, hippocampus) have been observed.
- Ri — CO — can be an acyl residue of a saturated organic acid, linear or branched, comprising from 10 to 20 C atoms
- R 2 can be: - an aminohydroxyalkyl residue, linear o branched, comprising from 2 to 6 C atoms, optionally substituted with one or more aromatic groups on the alkyl chain, and the hydroxyl group can be optionally esterified with a pharmaceutically suitable acid group, as for example acetic, tartaric and succinic or equivalent
- R3 can be H or CH 3 or where -N — R 2 .R3 forms with an atom of N a cyclic aminoether comprising from 5 to 7 C atoms optionally substituted with linear or branched alkyl groups,
- R 1 — CO — can be preferentially selected from the group constituted by aliphatic saturated monocarboxylic acids as for example decanoic acid, lauric, myristic, palmitic, stearic or arachidic acids and
- N — R2 when present as an aminohydroxyalkyl residue, can be preferentially chosen, for example, from the group constituted by monoethanolamine, 2- hydroxypropylamine, whilst when it is the residue of an ⁇ , ⁇ o ⁇ aminoacid it can be chosen from the group constituted by serine, glycine, ⁇ -alanine, ⁇ -aminobutyric, phenylalanine and tyrosine instead when -N — R 2 ,R 3 form, with an atom of N, a cyclic aminoether, this is preferentially morpholine.
- the saturated acylamides described in the present invention can be prepared according to various methods and preferably through fusion of the alkylamine salt with a carboxylic acid and formation of the corresponding alkylamide, or through acylation of the alkylamine nitrogen with appropriate activated carboxylic derivatives. Following are reported, for illustration, and not limiting purpose, some examples of saturated monocarboxylic acid amides.
- Example 1 Preparation of N-(2-hydroxyethyl)-palmitoyl amide
- the reaction mixture has then been crystallised from 95% ethanol.
- the crystalline body has been then separated by filtration using a buchner, washed three times with cold 95% ethanol and then taken to dryness under vacuum.
- the yield of the reaction has been approximately 85%.
- Example 5 Preparation of N-palmitoyl-morpholinamide
- morpholine 8.6 mmol
- triethylamine 9 mmol
- dimethylformamide 50 ml
- To the solution have been added, dropwise, 2.35 g of palmitoyl chloride (8.5 mmol) dissolved in dimethylformamide, and made to react for 1 hour at 0°C and for 5 hours at room temperature.
- the suspension obtained has been taken to dryness in a evaporator at reduced pressure.
- the solid residue has then been washed with ethyl ether and crystallised from 70% ethanol.
- the crystalline body was separated by filtration using a buchner, washed three times with cold 70% ethanol and then taken to dryness under vacuum.
- the yield of the reaction has been approximately 85%.
- Example 13 Preparation of N-palmitoyl- ⁇ -alanine 1.5 g of ⁇ -alanine (17 mmol) have been dissolved at 4°C in 1 M potassium hydroxide. To the solution have been added, dropwise and with continuous stirring, 2.75 g of palmitoyl chloride (10 mmol). The reaction mixture has been maintained at 0°C for 16 hours and, following this time, acidified with 6N HCI and extracted with ethyl acetate. The organic phase has been anhydrated with sodium sulphate and evaporated in a evaporator under reduced pressure. The residue was crystallised from (tert-butyl) methylether. The crystalline residue, separated by filtration using a buchner, has been washed three times with cold (tert-butyl) methylether and taken to dryness under vacuum.
- the yield of the reaction has been approximately 80%.
- the saturated fatty acid amide derivatives herein described have surprisingly been demonstrated to act, after repeated administration in normal adult rats, as functional antagonists of the central cannabinoid receptors, in that a reduction of the number of receptors or of their affinity, results in a reduction of their activity, without determining the cannabinomimetic effects known to be modulated by the central receptors (e.g. hypothermia, motor deficiency, etc.).
- the derivatives described in the present invention decrease food intake both after acute or chronic administration.
- the effects on the drastic reduction of the number of the central receptors at the level of the spinal medulla and the significant diminution of the affinity of this receptor in other areas of the CNS are described below in detail. Also described below is the behavioural/pharmacological effect on food intake and body weight after administration of compounds of the present invention.
- the cannabinoid receptors have been characterised using receptor binding techniques. These analyses have been carried out on cells membrane preparations from different areas of the CNS from animals treated repeatedly with the compounds described herein and compared with animals treated with just carrier. a) Treatment of animals
- Rats Male male Sprague Dawley rats have been used, weighing 200-300 g (Harlan- Italy, San Pietro al Natisone, UD, Italia). The animals, maintained on "normal" diets, have received two daily administrations (10mg/Kg peros) of the compounds herein described, for 10 days.
- the nervous tissue membranes have been prepared by the removal and rapid freezing at -80°C of the following cerebral areas: spinal medulla, cortex, hippocampus and cerebellum.
- the tissue have been weighed and suspended in 30 volumes of cold 50 mM Tris-HCI pH 7.4 buffer containing 0.25% of Soybean Type II Trypsin inhibitor, 1 mM EDTA and 4mM MgCb, and has been homogenised with 10 "strokes" in a Potter Teflon/glass homogeniser. After successive centrifugation and washing of the membranes, the pellet has been resuspended in a small volume (approx 1.5ml per g of starting tissue wet weight) of 50 mM Tris-HCI pH 7.4 buffer containing 1 mM EDTA, 4mM MgCI2 and 0.05% Fatty Acid Free BSA. Protein concentration has been determined on these samples by the bicinchinonic acid method.
- the 3 H-WIN55,212-2 possessing a high affinity for the central cannabinoid receptors, has been used at a concentration of around 1-2 nM, whilst the final concentration of cold WIN55.212-2 used to obtain the total displacement of the label from its receptors was from 1 to 10 ⁇ M.
- the final volume was 1ml, constituted by: 870 ⁇ l of binding buffer, 10 ⁇ l of DMSO, 10 ⁇ l of 3 H-WIN55,212-2 100nM, 10 ⁇ l of PMSF 1mM in 1% DMSO and 100 ⁇ l of synaptosomal membrane enriched preparation from nervous tissue (concentration of the homogenate around 1-2 ⁇ g of protein per ⁇ l).
- mice (18-22 g) were housed single per cage under standard conditions. Drugs were dissolved in a vehicle consisting of cremophor/ethanol/saline (1:1 :18 by volume) or suspended in carboxymethylcellulse (CMC) 0.5% in PBS.
- CMC carboxymethylcellulse
- Results are presented as means + SEM and were analysed with an analysis of variance ANOVA followed by Student-Newman-Keuls' test with the level of significance set at P-0.05.
- acylamides obtained following systemic administration in vivo described in the present invention, characterise these compounds as functional antagonists of the central cannabinoid receptors usefully employable therefore for the preparation of pharmaceutical compositions for the therapeutic treatment, alone or in association with other therapeutic agents selected for the specific pathological state or disorders, as for example drugs: anti-epileptics, neuroleptics, atypical neuroleptics, anti-depressives, dopaminergics, dopamine agonists, gaba agonists, weight control drugs, for memory improvement, anti-inflammatory/anti-pain (e.g..
- opiods salicilates, pyrazoles, indoles, arylanthranyles, arylpropionates, arylacetates, oxicam, pyrano carboxylates, glucocorticoids), cathartics (emollients, osmotics, salines, irritants), of pathologic states or disorder connected with altered functionality and/or "abusive" activation of the central cannabinoid receptors and as such in:
- the administration routes that can be used for the preventive or therapeutic treatment of the pathological states or disorders according to the present invention can be oral, parenteral, intramuscularly, subcutaneous or intravenously, and the topical administrations can be transdermical, including rectal, sublingual and intranasal.
- the compounds, according to the therapeutic use as functional antagonists of the central cannabinoid receptors can be administered in pharmaceutical compositions in combination with excipients, dispersants and diluents compatible with the pharmaceutical uses known or new, with the aim of obtaining an improved delivery of the active ingredient to the site of action and to obtain a rapid effect, sustained or delayed in time. For this aim therefore fast, sustained or slow release pharmaceutical compositions can be used.
- the dosages are dependent on the severity of the pathology or disorder and on the chosen route of administration, as well as on the state (age, body weight, general health condition) of the patient.
- the dosage may range between 1 mg/Kg and 50 mg/Kg in daily repeated administrations for a period ranging from 2 to 16 weeks.
- compositions in the form of dispersible granular powders, tablets, pills, hard and soft gelatine capsules, suspensions are suitable; for parenteral administration intramuscularly, subcutaneously, intravenously or peridurally, compositions in the form of buffered aqueous solutions, oil suspensions or lyophilised powders dispersible in appropriate solvents at the time of administration can be suitable; for topical administration transdermally, rectally, intranasally or sublingually, compositions in appropriate excipients or dispersants in the form of patches, suppositories, ovules, aerosols and sprays can be suitable.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02764671A EP1425004A1 (en) | 2001-07-11 | 2002-07-11 | Use of compounds as functional antagonists to the central cannabinoid receptors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2001MI001483A ITMI20011483A1 (en) | 2001-07-11 | 2001-07-11 | USE OF COMPOUNDS AS FUNCTIONAL ANTAGONISTS TO CENTRAL DEICANNABINOID RECEPTORS |
ITMI2001A001483 | 2001-07-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003006007A1 true WO2003006007A1 (en) | 2003-01-23 |
Family
ID=11448045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/007722 WO2003006007A1 (en) | 2001-07-11 | 2002-07-11 | Use of compounds as functional antagonists to the central cannabinoid receptors |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1425004A1 (en) |
IT (1) | ITMI20011483A1 (en) |
WO (1) | WO2003006007A1 (en) |
Cited By (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6467725B1 (en) | 1999-05-05 | 2002-10-22 | Lucas Industries Limited | Electrical generator an aero-engine including such a generator, and an aircraft including such a generator |
WO2004002986A2 (en) | 2002-06-28 | 2004-01-08 | Banyu Pharmaceutical Co., Ltd. | Novel benzimidazole derivatives |
WO2004069240A2 (en) * | 2003-02-07 | 2004-08-19 | Research & Innovation Soc. Coop. A. R. L. | Use in therapy of endocannabinoid-like compounds |
EP1449517A1 (en) * | 2003-02-21 | 2004-08-25 | Societe D'exploitation De Produits Pour Les Industries Chimiques, S.E.P.P.I.C. | Use of N-Lauroylaminoacids as cosmetic and pharmaceutical slimming agents |
WO2005028438A1 (en) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
WO2005073164A1 (en) * | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
US6972295B2 (en) | 2002-03-12 | 2005-12-06 | Merck & Co., Inc. | Substituted amides |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
WO2006129826A1 (en) | 2005-05-30 | 2006-12-07 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
WO2007018248A1 (en) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | Pyridone compound |
WO2007024004A1 (en) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
WO2007029847A1 (en) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | Bicyclic aromatic substituted pyridone derivative |
WO2007049798A1 (en) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | Novel benzoxathiin derivative |
WO2007055418A1 (en) | 2005-11-10 | 2007-05-18 | Banyu Pharmaceutical Co., Ltd. | Aza-substituted spiro derivative |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
WO2008038692A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
US7390835B2 (en) | 2003-10-30 | 2008-06-24 | Merck & Co., Inc. | Aralkyl amines as cannabinoid receptor modulators |
US7405221B2 (en) | 2002-09-27 | 2008-07-29 | Merck & Co., Inc. | Substituted pyrimidines |
WO2008120653A1 (en) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | Indoledione derivative |
EP2088154A1 (en) | 2004-03-09 | 2009-08-12 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2009110510A1 (en) | 2008-03-06 | 2009-09-11 | 萬有製薬株式会社 | Alkylaminopyridine derivative |
WO2009119726A1 (en) | 2008-03-28 | 2009-10-01 | 萬有製薬株式会社 | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
WO2009133208A1 (en) | 2008-05-02 | 2009-11-05 | Novartis Ag | Improved fibronectin-based binding molecules and uses thereof |
WO2009154132A1 (en) | 2008-06-19 | 2009-12-23 | 萬有製薬株式会社 | Spirodiamine-diarylketoxime derivative |
WO2010013595A1 (en) | 2008-07-30 | 2010-02-04 | 萬有製薬株式会社 | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
WO2011069038A2 (en) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011138392A1 (en) | 2010-05-06 | 2011-11-10 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies |
WO2012022814A1 (en) | 2010-08-20 | 2012-02-23 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
WO2012069466A1 (en) | 2010-11-24 | 2012-05-31 | Novartis Ag | Multispecific molecules |
WO2012116145A1 (en) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
WO2013067355A1 (en) | 2011-11-04 | 2013-05-10 | Novartis Ag | Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs |
WO2013084148A2 (en) | 2011-12-05 | 2013-06-13 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
WO2013084147A2 (en) | 2011-12-05 | 2013-06-13 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
WO2014159239A2 (en) | 2013-03-14 | 2014-10-02 | Novartis Ag | Antibodies against notch 3 |
EP2810951A2 (en) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
WO2015051725A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP2998314A1 (en) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2017073797A1 (en) | 2015-10-28 | 2017-05-04 | Ajinomoto Co., Inc. | Immunostimulating agent |
WO2017125897A1 (en) | 2016-01-21 | 2017-07-27 | Novartis Ag | Multispecific molecules targeting cll-1 |
EP3241839A1 (en) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018132876A1 (en) * | 2017-01-19 | 2018-07-26 | The University Of Sydney | Novel glycine transport inhibitors for the treatment of pain |
US10100008B2 (en) | 2014-04-25 | 2018-10-16 | Ajinomoto Co., Inc. | Immunostimulating agent |
WO2018216008A1 (en) * | 2017-05-22 | 2018-11-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Fatty acid amides and uses thereof in the treatment of addiction disorder and addiction related conditions |
EP3409682A4 (en) * | 2016-01-25 | 2019-10-23 | Shenyang Pharmaceutical University | Compound and use thereof and platinum complex and lipidosome thereof |
WO2019229701A2 (en) | 2018-06-01 | 2019-12-05 | Novartis Ag | Binding molecules against bcma and uses thereof |
WO2020109978A1 (en) | 2018-11-26 | 2020-06-04 | Novartis Ag | Lpl-gpihbp1 fusion polypeptides |
WO2020236792A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Cd19 binding molecules and uses thereof |
WO2020236797A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Variant cd58 domains and uses thereof |
WO2022097060A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
WO2023209568A1 (en) | 2022-04-26 | 2023-11-02 | Novartis Ag | Multispecific antibodies targeting il-13 and il-18 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996018600A1 (en) * | 1994-12-14 | 1996-06-20 | Lifegroup S.P.A. | Amides of mono and bicarboxylic acids with amino acids or glycosamines, selectively active on the cannabinoid peripheral receptor |
US5925678A (en) * | 1994-03-21 | 1999-07-20 | Lifegroup S.P.A. | Use of N-acyl derivatives of aminoalcohols in the manufacture of a medicament for practicing neuroprotective action in neuropathological states connected with excitotoxicity |
US5990170A (en) * | 1994-12-14 | 1999-11-23 | Lifegroup S.P.A. | Therapeutic use of mono and bicarboxylic acid amides active at the peripheral cannabinoid receptor |
-
2001
- 2001-07-11 IT IT2001MI001483A patent/ITMI20011483A1/en unknown
-
2002
- 2002-07-11 WO PCT/EP2002/007722 patent/WO2003006007A1/en not_active Application Discontinuation
- 2002-07-11 EP EP02764671A patent/EP1425004A1/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925678A (en) * | 1994-03-21 | 1999-07-20 | Lifegroup S.P.A. | Use of N-acyl derivatives of aminoalcohols in the manufacture of a medicament for practicing neuroprotective action in neuropathological states connected with excitotoxicity |
WO1996018600A1 (en) * | 1994-12-14 | 1996-06-20 | Lifegroup S.P.A. | Amides of mono and bicarboxylic acids with amino acids or glycosamines, selectively active on the cannabinoid peripheral receptor |
US5990170A (en) * | 1994-12-14 | 1999-11-23 | Lifegroup S.P.A. | Therapeutic use of mono and bicarboxylic acid amides active at the peripheral cannabinoid receptor |
Non-Patent Citations (10)
Title |
---|
AMERI A: "The effects of cannabinoids on the brain.", PROGRESS IN NEUROBIOLOGY. ENGLAND JUL 1999, vol. 58, no. 4, July 1999 (1999-07-01), pages 315 - 348, XP001120318, ISSN: 0301-0082 * |
BÁTKAI S ET AL: "Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis.", NATURE MEDICINE. UNITED STATES JUL 2001, vol. 7, no. 7, July 2001 (2001-07-01), pages 827 - 832, XP001120431, ISSN: 1078-8956 * |
CAPASSO R ET AL: "Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice.", BRITISH JOURNAL OF PHARMACOLOGY. ENGLAND NOV 2001, vol. 134, no. 5, November 2001 (2001-11-01), pages 945 - 950, XP001120406, ISSN: 0007-1188 * |
IZZO A A ET AL: "MODULATION OF PERISTALSIS BY CANNABINOID CB1 LIGANDS IN THE ISOLATED GUINEA-PIG ILEUM", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 129, no. 5, March 2000 (2000-03-01), pages 984 - 990, XP000997205, ISSN: 0007-1188 * |
MARTIN B R ET AL: "Discovery and characterization of endogenous cannabinoids.", LIFE SCIENCES. ENGLAND 1999, vol. 65, no. 6-7, 1999, pages 573 - 595, XP001120432, ISSN: 0024-3205 * |
MAS-NIETO, MAGDALENA ET AL.: "Reduction of opiod dependence by the CB1 antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opiod addiction", BRIT. J. PHARMACOL., vol. 132, 2001, pages 1809 - 1816, XP009001232 * |
PUOMELLI, DANIEL ET AL.: "The endocannabinoid system as a target for therapeutic drugs", TIPS, vol. 22, 2000, pages 218 - 224, XP002222935 * |
RICE A S C: "CANNABINOIDS IN PAIN", CURRENT OPINION IN INVESTIGATIONAL DRUGS, CURRENT DRUGS, LONDON, GB, vol. 2, no. 3, March 2001 (2001-03-01), pages 399 - 414, XP001119594, ISSN: 0967-8298 * |
SALZET MICHEL ET AL.: "Comparative biology of the endocannabinoid system", EUR. J. BIOCHEM., vol. 267, 2000, pages 4917 - 4927, XP001120429 * |
VAMVAKIDES A: "CATALEPSIE CHEZ LE RAT APRES HALOPERIDOL ET QUELQUES NOUVEAUX GABA-ERGIQUES", AGRESSOLOGIE, XX, XX, vol. 25, no. 9, 3 December 1983 (1983-12-03), pages 1011 - 1016, XP002064200 * |
Cited By (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6467725B1 (en) | 1999-05-05 | 2002-10-22 | Lucas Industries Limited | Electrical generator an aero-engine including such a generator, and an aircraft including such a generator |
US6972295B2 (en) | 2002-03-12 | 2005-12-06 | Merck & Co., Inc. | Substituted amides |
WO2004002986A2 (en) | 2002-06-28 | 2004-01-08 | Banyu Pharmaceutical Co., Ltd. | Novel benzimidazole derivatives |
US7405221B2 (en) | 2002-09-27 | 2008-07-29 | Merck & Co., Inc. | Substituted pyrimidines |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
WO2004069240A3 (en) * | 2003-02-07 | 2004-11-11 | Res & Innovation Soc Coop A R | Use in therapy of endocannabinoid-like compounds |
EP1900365A3 (en) * | 2003-02-07 | 2008-07-23 | Research & Innovation Soc. Coop. A R.L. | Endocannabinoid-like compounds and their use |
WO2004069240A2 (en) * | 2003-02-07 | 2004-08-19 | Research & Innovation Soc. Coop. A. R. L. | Use in therapy of endocannabinoid-like compounds |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
FR2851460A1 (en) * | 2003-02-21 | 2004-08-27 | Seppic Sa | USE OF N-LAUROYL AMINOACIDS AS A SLIMMING COSMETIC AND PHARMACEUTICAL ACTIVE |
EP1449517A1 (en) * | 2003-02-21 | 2004-08-25 | Societe D'exploitation De Produits Pour Les Industries Chimiques, S.E.P.P.I.C. | Use of N-Lauroylaminoacids as cosmetic and pharmaceutical slimming agents |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7354929B2 (en) | 2003-04-23 | 2008-04-08 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
WO2005028438A1 (en) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
US7390835B2 (en) | 2003-10-30 | 2008-06-24 | Merck & Co., Inc. | Aralkyl amines as cannabinoid receptor modulators |
WO2005073164A1 (en) * | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
EP2088154A1 (en) | 2004-03-09 | 2009-08-12 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
WO2006129826A1 (en) | 2005-05-30 | 2006-12-07 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
WO2007018248A1 (en) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | Pyridone compound |
WO2007024004A1 (en) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
WO2007029847A1 (en) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | Bicyclic aromatic substituted pyridone derivative |
WO2007049798A1 (en) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | Novel benzoxathiin derivative |
WO2007055418A1 (en) | 2005-11-10 | 2007-05-18 | Banyu Pharmaceutical Co., Ltd. | Aza-substituted spiro derivative |
WO2008038692A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
WO2008120653A1 (en) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | Indoledione derivative |
EP2998314A1 (en) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2009110510A1 (en) | 2008-03-06 | 2009-09-11 | 萬有製薬株式会社 | Alkylaminopyridine derivative |
WO2009119726A1 (en) | 2008-03-28 | 2009-10-01 | 萬有製薬株式会社 | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
WO2009133208A1 (en) | 2008-05-02 | 2009-11-05 | Novartis Ag | Improved fibronectin-based binding molecules and uses thereof |
EP2383292A1 (en) | 2008-05-02 | 2011-11-02 | Novartis AG | Improved fibronectin-based binding molecules and uses thereof |
EP3173424A1 (en) | 2008-05-02 | 2017-05-31 | Novartis Ag | Improved fibronectin-based binding molecules and uses thereof |
EP2439212A1 (en) | 2008-05-02 | 2012-04-11 | Novartis AG | Improved fibronectin-based binding molecules and uses thereof |
EP2810951A2 (en) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2009154132A1 (en) | 2008-06-19 | 2009-12-23 | 萬有製薬株式会社 | Spirodiamine-diarylketoxime derivative |
EP3241839A1 (en) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2010013595A1 (en) | 2008-07-30 | 2010-02-04 | 萬有製薬株式会社 | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
WO2011069038A2 (en) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EP2923706A1 (en) | 2009-12-03 | 2015-09-30 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia |
WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EP3345926A1 (en) | 2010-05-06 | 2018-07-11 | Novartis AG | Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies |
EP4234698A2 (en) | 2010-05-06 | 2023-08-30 | Novartis AG | Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies |
WO2011138392A1 (en) | 2010-05-06 | 2011-11-10 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies |
WO2012022814A1 (en) | 2010-08-20 | 2012-02-23 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
WO2012069466A1 (en) | 2010-11-24 | 2012-05-31 | Novartis Ag | Multispecific molecules |
WO2012116145A1 (en) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
EP3243385A1 (en) | 2011-02-25 | 2017-11-15 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
WO2013067355A1 (en) | 2011-11-04 | 2013-05-10 | Novartis Ag | Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs |
EP3290442A1 (en) | 2011-11-04 | 2018-03-07 | Novartis AG | Low density lipoprotein-related protein 6 (lrp6) half-life extender constructs |
EP3252075A1 (en) | 2011-11-04 | 2017-12-06 | Novartis AG | Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs |
WO2013084147A2 (en) | 2011-12-05 | 2013-06-13 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
WO2013084148A2 (en) | 2011-12-05 | 2013-06-13 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
EP3590538A1 (en) | 2011-12-05 | 2020-01-08 | Novartis AG | Antibodies for epidermal growth factor receptor 3 (her3) |
WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
EP3708179A1 (en) | 2012-03-15 | 2020-09-16 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
EP4309673A2 (en) | 2012-03-15 | 2024-01-24 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014159239A2 (en) | 2013-03-14 | 2014-10-02 | Novartis Ag | Antibodies against notch 3 |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
WO2015051725A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US10100008B2 (en) | 2014-04-25 | 2018-10-16 | Ajinomoto Co., Inc. | Immunostimulating agent |
EP3511318A1 (en) | 2015-10-28 | 2019-07-17 | Ajinomoto Co., Inc. | Immunostimulating agent |
WO2017073797A1 (en) | 2015-10-28 | 2017-05-04 | Ajinomoto Co., Inc. | Immunostimulating agent |
WO2017125897A1 (en) | 2016-01-21 | 2017-07-27 | Novartis Ag | Multispecific molecules targeting cll-1 |
EP3851457A1 (en) | 2016-01-21 | 2021-07-21 | Novartis AG | Multispecific molecules targeting cll-1 |
EP3409682A4 (en) * | 2016-01-25 | 2019-10-23 | Shenyang Pharmaceutical University | Compound and use thereof and platinum complex and lipidosome thereof |
US10730898B2 (en) | 2016-01-25 | 2020-08-04 | Sheyang Pharmaceutical University | Compound and use thereof and platinum complex and lipidosome thereof |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018132876A1 (en) * | 2017-01-19 | 2018-07-26 | The University Of Sydney | Novel glycine transport inhibitors for the treatment of pain |
JP2020520954A (en) * | 2017-05-22 | 2020-07-16 | イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド | Fatty acid amides and the use of fatty acid amides in the treatment of addictive disorders and addiction related conditions |
CN110869014A (en) * | 2017-05-22 | 2020-03-06 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | Fatty acid amides and their use in treating addictive disorders and addiction-related conditions |
WO2018216008A1 (en) * | 2017-05-22 | 2018-11-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Fatty acid amides and uses thereof in the treatment of addiction disorder and addiction related conditions |
US11324709B2 (en) * | 2017-05-22 | 2022-05-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Fatty acid amides and uses thereof in the treatment of addiction disorder and addiction related conditions |
WO2019229701A2 (en) | 2018-06-01 | 2019-12-05 | Novartis Ag | Binding molecules against bcma and uses thereof |
WO2020109978A1 (en) | 2018-11-26 | 2020-06-04 | Novartis Ag | Lpl-gpihbp1 fusion polypeptides |
WO2020236797A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Variant cd58 domains and uses thereof |
WO2020236792A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Cd19 binding molecules and uses thereof |
WO2022097060A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
WO2023209568A1 (en) | 2022-04-26 | 2023-11-02 | Novartis Ag | Multispecific antibodies targeting il-13 and il-18 |
Also Published As
Publication number | Publication date |
---|---|
EP1425004A1 (en) | 2004-06-09 |
ITMI20011483A1 (en) | 2003-01-11 |
ITMI20011483A0 (en) | 2001-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003006007A1 (en) | Use of compounds as functional antagonists to the central cannabinoid receptors | |
JP4216330B2 (en) | Use of mono- and bicarboxylic amides in the manufacture of drugs acting at peripheral cannabinoid receptors | |
JP4111349B2 (en) | Amides of mono- and bicarboxylic acids with amino acids or glycosamines that act selectively on peripheral cannabinoid receptors | |
KR20080047956A (en) | Pharmaceutical composition for treatment and prevention of diseases involving impotence | |
JP2010512413A (en) | Non-standard amino acid conjugates of amphetamine and methods for their production and use | |
AU2012327209B2 (en) | Compositions and methods for the modulation of specific amidases for N-acylethanolamines for use in the therapy of inflammatory diseases | |
JPH08512048A (en) | Immunosuppressive and anti-allergic compounds such as N- (3-oxyhexanoyl) homoserine lactone | |
CA2722491C (en) | Pharmaceutical formulation containing palmitoyl ethanolamide and stearoyl ethanolamide | |
AU2017341769B2 (en) | N-Acylethanolamide derivatives and uses thereof | |
WO2016014242A1 (en) | Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods | |
EP1592418B1 (en) | Use of endocannabinoid-like compounds for treating cns degenerative disorders | |
AU737454B2 (en) | Method for inhibiting the growth of mammalian cells | |
WO2016193905A1 (en) | Combination comprising palmitoylethanolamide (pea) and lycopene for use in the treatment of inflammatory diseases | |
WO1990003171A1 (en) | 26-aminocholesterol and derivatives and analogs thereof in the regulation of cholesterol accumulation in body tissue | |
CN116133693A (en) | Drug-loaded macromolecule and preparation method thereof | |
JPH09510467A (en) | Use of N-acyl derivatives of aminoalcohols in the manufacture of a medicament having a neuroprotective effect in neuropathological conditions associated with excitotoxicity | |
JP2021504315A (en) | Polymorphs and their use | |
CN114621242A (en) | Galantamine derivatives and formulations | |
TW541295B (en) | A novel substituted alkylteraamine derivative for use as tachykinin antagonist | |
TW399056B (en) | Long analgesic acting nalbuphine polyester derivative and method of use | |
WO2023287984A1 (en) | Suberoylanilide hydroxamic acid (saha) drugs, conjugates, and nanoparticles, and methods of use thereof | |
WO2024015447A1 (en) | Preparation of stable psilocin salts, esters and conjugates and uses thereof | |
LV15575B (en) | DEITERATED ANALOGS OF SELENOPHENCHROMENE, THEIR PREPARATION AND USE | |
JPH0881365A (en) | Inhibitor for oxidation stress |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002764671 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2002764671 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |